Efgartigimod PH20 SC

Phase 3

argenx SE (ARGX)

00%

What is LOA?

Phase 3

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

Upcoming Catalysts

What are catalysts?

Sep '27

ARGXPhase 3$58.8B

Efgartigimod PH20 SC Phase 3 Est. Readout

Efgartigimod PH20 SC• Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)12

Sep 2027~Confirmed

CT.gov

00%

Jul '27

ARGXPhase 3$58.8B

Efgartigimod PH20 SC Phase 3 Est. Readout

Efgartigimod PH20 SC• Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)631

Jul 2027~Confirmed

CT.gov

00%

Q2 '27

ARGXPhase 2$58.8B

Efgartigimod PH20 SC Phase 2 Est. Readout

Efgartigimod PH20 SC• Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)229

Q2 2027~QConfirmed

CT.gov

00%

Development History

Oct '26

ARGXPhase 3$58.8B

✓Positive

Efgartigimod PH20 SC Phase 3 Est. Readout

Efgartigimod PH20 SC• Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)173

Oct 2026~Confirmed

CT.gov

Competitive Landscape

0 competitors in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

View Full Landscape

Drug Information

Target Indication

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

Clinical Trial

NCT04280718

Last updated: 1/2/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Source: FDA Orange Book

Drug Science

Mechanism of action & safety profile

Developer

ARGX

argenx SE

Biological Products, (No Diagnostic Substances)•Europe•NASDAQ

Related Pipeline

ARGX-113Phase 3

Pemphigus Vulgaris

EFG PH20 SCPhase 3

Active Idiopathic Inflammatory Myopathy

IVIG (Intravenous Immunoglobulin)Phase 3

Multifocal Motor Neuropathy (MMN)

EfgartigimodPhase 3

Postural Orthostatic Tachycardia Syndrome

Efgartigimod IVPhase 3

Generalized Myasthenia Gravis

View full pipeline

Get Catalyst Alerts

Receive weekly digests of upcoming catalysts